Placebo - saline

DRUG4 trials

Sponsors

Stanford University, Theravance Biopharma, Dayton VA Medical Center, University Hospital Hradec Kralove

Conditions

COPDDyspneaGastrointestinal Motility DisorderPain

Phase 1

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

TerminatedNCT01644240

Theravance BiopharmaGastrointestinal Motility Disorder

Start: 2012-09-30End: 2012-12-31Updated: 2017-08-02

Phase 2

The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases

RecruitingNCT06252454

University Hospital Hradec KraloveDyspnea

Start: 2024-02-27End: 2025-12-31Target: 102Updated: 2024-04-16

Phase 4

Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

WithdrawnNCT02773797

Dayton VA Medical CenterCOPD

Start: 2016-08-31End: 2018-04-30Updated: 2018-07-31

Unknown Phase

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

CompletedNCT00725322

Stanford UniversityPain

Start: 2007-12-31End: 2013-03-31Updated: 2017-10-25